中国生物工程杂志

［1］ Harris J M, Chess R B. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2003, 2:214221. 
［2］ Walsh G. Biopharmaceutical benchmarks. Nature Biotechnology, 2000, 18: 831833. 
［3］ Ryan S M, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opinion Drug Delivery, 2008, 5(4):371383. 
［4］ Veronese F M, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today, 2005, 10(21):14511458. 
［5］ Fishburn C S. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. Journal of Pharmaceutical Sciences, 2008, 97(10): 41674183. 
［6］Veronese F M, Pasut G. PEGylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discovery Today: Technologies, 2008, 5(23):e57e64. 
［7］ 王凤山, 赵婷, 袁勤生. 蛋白质和多肽的PEG定点修饰研究进展. 2008年中国药学会学术年会暨第八届中国药师周论文集, 2008:23212332. 
［8］ 付正明，王洪权，丁建新，等. 蛋白质多肽药物聚乙二醇定点修饰的研究进展. 军事医学科学院院刊, 2007,31(2):178182. Fu Z M, Wang H Q, Ding J X, et al. Bulletin of the Academy of Military Medical Sciences, 2007,31(2):178182. 
［9］ 董惠钧，姜俊云，郑立军，等. 蛋白药物聚乙二醇修饰技术研究进展. 中国生化药物杂志,2009,30 (3 ):199203. Dong H J, Jiang J Y, Zheng L J, et al. Chinese Journal of Biochemical Pharmaceutics,2009,30 (3 ):199203. 
［10］ Veronese F M, Pasut G. Polymerdrug conjugation, recent achievements and general strategies. Progress in Polymer Science, 2007, 32: 933961. 
［11］ Yoshioka Y, Tsutsumi Y, Ikemizu S, et al. Optimal sitespecific PEGylation of mutant TNFa improves its antitumor potency. Biochemical and Biophysical Research Communications, 2004, 315: 808814. 
［12］ Youn Y S, Kwon M J, Na D H, et al. Improved intrapulmonary delivery of sitespecific PEGylated salmon calcitonin: Optimization by PEG size selection. Journal of Controlled Release, 2008, 125:6875. 
［13］ Fee C J. Sizeexclusion reaction chromatography (SERC): A new technique for protein PEGylation. Biotechnology and Bioengineering, 2003, 82(2): 200206. 
［14］ Baran E T, Ozer N, Hasirci V. Solidphase enzyme modification via affinity chromatography. Journal of Chromatography B, 2003, 794:311322. 
［15］ Lee B K, Kwon J S, Kim H J, et al. Solidphase PEGylation of recombinant interferon alpha2a for sitespecific modification: process performance, characterization, and in vitro bioactivity. Bioconjugate Chemistry, 2007, 18(6):17281734. 
［16］ Suo X Y, Lu X L, Hu T, et al. A solidphase adsorption method for PEGylation of human serum albumin and staphylokinase: preparation, purification and biochemical characterization. Biotechnology Letters, 2009, 31:11911196. 
［17］ Suo X Y, Zheng C Y, Yu PZ, et al. Solid phase pegylation of hemoglobin. Artificial Cells, Blood Substitutes, and Biotechnology, 2009, 12:19. 
［18］ Hou B B, Li S R, Li X H, et al. Design, preparation and in vitro bioactivity of monopegylated recombinant hirudin. Chinese Journal of Chemical Engineering,2007,15(6):775780. 
［19］ 修志龙,李雪芹,李晓晖.一种利用阴离子交换柱辅助聚乙二醇修饰水蛭素的方法：中国专利，200810011554.6, 20081008. Xiu Z L, Li X Q, Li X H. Chinese Patent, 200810011554.6, 20081008. 
［20］ Lu Y A, Felix A M. Pegylated peptides II: Solidphase synthesis of amino, carboxy and sidechain pegylated peptides. International Journal of Peptide & Protein Research.,1994, 43(2):127138. 
［21］ Kinstler O, Molineux G, Treuheit M, et al. MonoNterminal poly (ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 2002, 54: 477485. 
［22］ Youn Y S, Na D H, Lee K C. Highyield production of biologically active monoPEGylated salmon calcitonin by sitespecific PEGylation. Journal of Controlled Release, 2007, 117: 371379. 
［23］ Youn Y S, Lee K C. Sitespecific PEGylation for highyield preparation of Lys21amine PEGylated growth hormonereleasing factor (GRF) (129) using a GRF(129) derivative FMOCprotected at Tyr1 and Lys12. Bioconjugate Chemistry, 2007, 18:500506. 
［24］ Youn Y S, Chae S Y, Lee S, et al. Evaluation of therapeutic potentials of sitespecific PEGylated glucagonlike peptide1 isomers as a type 2 antidiabetic treatment, insulinotropic activity, glucosestabilizing capability, and proteolytic stability. Biochemical Pharmacolocy, 2007, 73:8493. 
［25］ Chae S Y, Chun Y G, Lee S, et al. Pharmacokinetic and pharmacodynamic evaluation of sitespecific PEGylated glucagonlike peptide1 analogs as flexible postprandialglucose controllers. Journal of Pharmaceutical Sciences, 2009, 98(4): 15561567. 
［26］ Balan S, Choi J W, Godwin A, et al. Sitespecific PEGylation of protein disulfide bonds using a threecarbon bridge. Bioconjugate Chemistry, 2007, 18:6176. 
［27］ Balan S, Brocchini S, Godwin A, et al. Disulfide bridge based PEGylation of proteins. Advanced Drug Delivery Reviews, 2008, 60(1):312. 
［28］ 李智华，胡满仓，阎玲梅，等. 人白细胞介素11的定点聚乙二醇修饰. 中国生物工程杂志,2009,29(6):2024. Li Z H, Hu M C, Yan L M, et al. China Biotechnology, 2009,29(6):2024. 
［29］ Chi Y S, Zhang H B, Huang W L, et al. Microwaveassisted solid phase synthesis, PEGylation, and biological activity studies of glucagonlike peptide1(7–36) amide. Bioorganic & Medicinal Chemistry, 2008, 16:76077614. 
［30］ Fontana A, Spolaore B, Mero A, et al. Sitespecific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Advanced Drug Delivery Reviews, 2008, 60: 1328. 
［31］ Mero A, Spolaore B, Veronese F M, et al. Transglutaminasemediated PEGylation of proteins: direct identification of the sites of protein modificationby mass spectrometry using a novel monodisperse PEG. Bioconjugate Chemistry, 2009, 20 (2):384389. 
［32］ Foser S, Schacher A, Weyer K A, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α2a (PEGASYS). Protein Expression and Purification, 2003, 30:7887. 
［33］ Lee K C, Moon S C, Park M O, et al. Isolation, characterization, and stability of positional isomers of monoPEGylated salmon calcitonins. Pharmaceutical Research, 1999, 16:813818. 
［34］ Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormonereleasing hormone (GRF) analogues. Advanced Drug Delivery Reviews, 2003, 55:12791291. 
［35］ Youn Y S, Na D H, Yoo S D, et al. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycolmodified growth hormonereleasing factor (129). Journal of Chromatography A, 2004, 1061:4549. 
［36］Na D H, Park E J, Jo Y W, et al. Capillary electrophoretic separation of highmolecularweight poly(ethylene glycol)modified proteins. Analytical Biochemistry, 2008, 373(2):207212. 
［37］ Veronese F M, Sacca B, Polverino de Laureto P, et al. New PEGs for peptide and protein modification, suitable for identification of the PEGylation site. Bioconjugate Chemistry, 2001, 12(1): 6270. 
［38］ Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEGInterferonα2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjugate Chemistry, 2005, 16 (3):518527. 
［39］ 胡远东，白坚石，焦克芳，等. PEG修饰牛血红蛋白的计算机模拟研究. 生物物理学 报,2000,16(2 ):315321. Hu Y D, Bai J S, Jiao K F, et al. Acta Biophysica Sinica,2000,16(2 ):315321. 
［40］ 赵军，李雪芹，修志龙. PEG在线定点修饰水蛭素及其修饰位点的理论预测与分析. 高等学校化学学报,2009,30(7): 14101416. Zhao J, Li X Q, Xiu Z L. Chemical Journal of Chinese Universities,2009,30(7): 14101416. 
［41］ Digilio G, Barbero L, Bracco C, et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormonereleasing factor, hGRF(129)NH2. Journal of the American Chemical Society, 2003, 125 (12):34583470. 
［42］ Svergun D I, Ekstrom F, Vandergriff K D, et al. Solution structure of poly(ethylene) glycolconjugated hemoglobin revealed by smallangle Xray scattering: implications for a new oxygen therapeutic. Biophysical Journal, 2008, 94: 173181. 
［43］ Dhalluin C, Ross A, Leuthold L A, et al. Structural and biophysical characterization of the 40 kDa PEGInterferonα2a and its individual positional isomers. Bioconjugate Chemistry, 2005, 16 (3):504517. 
［44］ Zloh M, Shaunak S, Balan S, et al. Identification and insertion of 3carbon bridges in protein disulfide bonds: a computational approach. Nature Protocols, 2007, 2:10701083.